Cargando…

Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects

SIMPLE SUMMARY: For breast cancer patients who do not wish to undergo any form of surgery, various non-surgical treatments have been investigated. Radiotherapy is considered the most important modality, but conventional radiotherapy alone or concurrent chemoradiotherapy do not lead to high local con...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibamoto, Yuta, Takano, Seiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046665/
https://www.ncbi.nlm.nih.gov/pubmed/36980750
http://dx.doi.org/10.3390/cancers15061864
_version_ 1785013730102214656
author Shibamoto, Yuta
Takano, Seiya
author_facet Shibamoto, Yuta
Takano, Seiya
author_sort Shibamoto, Yuta
collection PubMed
description SIMPLE SUMMARY: For breast cancer patients who do not wish to undergo any form of surgery, various non-surgical treatments have been investigated. Radiotherapy is considered the most important modality, but conventional radiotherapy alone or concurrent chemoradiotherapy do not lead to high local control rates. So, to increase curability, radiosensitization strategies, including the use of hydrogen peroxide injection before radiation and hyperthermia plus oral tegafur-gimeracil-oteracil potassium (S-1), have been investigated. These strategies have yielded promising outcomes, with local control rates of ~97%. A trial of carbon ion radiotherapy is ongoing, and particle therapy should be further investigated in the future. Image-guided ablation therapy including radiofrequency ablation and focused ultrasound have been investigated; although complete ablation rates of ≥70% have been reported, combination with radiotherapy may be necessary to treat the extensive intraductal components. Non-surgical treatment of breast cancer is evolving steadily and will become a valuable treatment option for patients who refuse surgery. ABSTRACT: This article reviews the results of various non-surgical curative treatments for operable breast cancer. Radiotherapy is considered the most important among such treatments, but conventional radiotherapy alone and concurrent chemoradiotherapy do not achieve high cure rates. As a radiosensitization strategy, intratumoral injection of hydrogen peroxide before radiation has been investigated, and high local control rates (75–97%) were reported. The authors treated 45 patients with whole-breast radiotherapy, followed by stereotactic or intensity-modulated radiotherapy boost, with or without a radiosensitization strategy employing either hydrogen peroxide injection or hyperthermia plus oral tegafur-gimeracil-oteracil potassium. Stages were 0–I in 23 patients, II in 19, and III in 3. Clinical and cosmetic outcomes were good, with 5-year overall, progression-free, and local recurrence-free survival rates of 97, 86, and 88%, respectively. Trials of carbon ion radiotherapy are ongoing, with promising interim results. Radiofrequency ablation, focused ultrasound, and other image-guided ablation treatments yielded complete ablation rates of 20–100% (mostly ≥70%), but long-term cure rates remain unclear. In these treatments, combination with radiotherapy seems necessary to treat the extensive intraductal components. Non-surgical treatment of breast cancer is evolving steadily, with radiotherapy playing a major role. In the future, proton therapy with the ultra-high-dose-rate FLASH mode is expected to further improve outcomes.
format Online
Article
Text
id pubmed-10046665
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100466652023-03-29 Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects Shibamoto, Yuta Takano, Seiya Cancers (Basel) Review SIMPLE SUMMARY: For breast cancer patients who do not wish to undergo any form of surgery, various non-surgical treatments have been investigated. Radiotherapy is considered the most important modality, but conventional radiotherapy alone or concurrent chemoradiotherapy do not lead to high local control rates. So, to increase curability, radiosensitization strategies, including the use of hydrogen peroxide injection before radiation and hyperthermia plus oral tegafur-gimeracil-oteracil potassium (S-1), have been investigated. These strategies have yielded promising outcomes, with local control rates of ~97%. A trial of carbon ion radiotherapy is ongoing, and particle therapy should be further investigated in the future. Image-guided ablation therapy including radiofrequency ablation and focused ultrasound have been investigated; although complete ablation rates of ≥70% have been reported, combination with radiotherapy may be necessary to treat the extensive intraductal components. Non-surgical treatment of breast cancer is evolving steadily and will become a valuable treatment option for patients who refuse surgery. ABSTRACT: This article reviews the results of various non-surgical curative treatments for operable breast cancer. Radiotherapy is considered the most important among such treatments, but conventional radiotherapy alone and concurrent chemoradiotherapy do not achieve high cure rates. As a radiosensitization strategy, intratumoral injection of hydrogen peroxide before radiation has been investigated, and high local control rates (75–97%) were reported. The authors treated 45 patients with whole-breast radiotherapy, followed by stereotactic or intensity-modulated radiotherapy boost, with or without a radiosensitization strategy employing either hydrogen peroxide injection or hyperthermia plus oral tegafur-gimeracil-oteracil potassium. Stages were 0–I in 23 patients, II in 19, and III in 3. Clinical and cosmetic outcomes were good, with 5-year overall, progression-free, and local recurrence-free survival rates of 97, 86, and 88%, respectively. Trials of carbon ion radiotherapy are ongoing, with promising interim results. Radiofrequency ablation, focused ultrasound, and other image-guided ablation treatments yielded complete ablation rates of 20–100% (mostly ≥70%), but long-term cure rates remain unclear. In these treatments, combination with radiotherapy seems necessary to treat the extensive intraductal components. Non-surgical treatment of breast cancer is evolving steadily, with radiotherapy playing a major role. In the future, proton therapy with the ultra-high-dose-rate FLASH mode is expected to further improve outcomes. MDPI 2023-03-20 /pmc/articles/PMC10046665/ /pubmed/36980750 http://dx.doi.org/10.3390/cancers15061864 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Shibamoto, Yuta
Takano, Seiya
Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects
title Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects
title_full Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects
title_fullStr Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects
title_full_unstemmed Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects
title_short Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects
title_sort non-surgical definitive treatment for operable breast cancer: current status and future prospects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046665/
https://www.ncbi.nlm.nih.gov/pubmed/36980750
http://dx.doi.org/10.3390/cancers15061864
work_keys_str_mv AT shibamotoyuta nonsurgicaldefinitivetreatmentforoperablebreastcancercurrentstatusandfutureprospects
AT takanoseiya nonsurgicaldefinitivetreatmentforoperablebreastcancercurrentstatusandfutureprospects